Cargando…

Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study

INTRODUCTION: Parkinson’s disease (PD) patients in chronic levodopa treatment may experience motor and non-motor fluctuations, which may affect their quality of life. Safinamide is a new monoamine oxidase B inhibitor, also exerting a non-dopaminergic effect, recently approved as add-on therapy in fl...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Micco, Rosa, Satolli, Sara, Siciliano, Mattia, De Mase, Antonio, Giordano, Alfonso, Tedeschi, Gioacchino, Tessitore, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724100/ https://www.ncbi.nlm.nih.gov/pubmed/34031800 http://dx.doi.org/10.1007/s10072-021-05324-w

Ejemplares similares

Sensorimotor Connectivity in Parkinson’s Disease: The Role of Functional Neuroimaging
por: Tessitore, Alessandro, et al.
Publicado: (2014)

Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study
por: De Masi, Claudia, et al.
Publicado: (2022)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Correlates of the discrepancy between objective and subjective cognitive functioning in non-demented patients with Parkinson’s disease
por: Siciliano, Mattia, et al.
Publicado: (2021)

Correlates of psychological distress in epileptic patients during the COVID-19 outbreak
por: Giordano, Alfonso, et al.
Publicado: (2021)

Correlates of psychological distress in epileptic patients during the COVID-19 outbreak
por: Giordano, Alfonso, et al.
Publicado: (2021)

Validation of new diagnostic criteria for fatigue in patients with Parkinson disease
por: Siciliano, Mattia, et al.
Publicado: (2022)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
por: Pauletti, Caterina, et al.
Publicado: (2023)

Impulse Control Behaviors in Parkinson's Disease: Drugs or Disease? Contribution From Imaging Studies
por: De Micco, Rosa, et al.
Publicado: (2018)

Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson’s Disease Patients
por: Cattaneo, Carlo, et al.
Publicado: (2020)

A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease
por: Abdelalem Aziz Ahmed, Mohamed
Publicado: (2019)

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
por: Gómez-López, Ana, et al.
Publicado: (2021)

Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2021)

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Non-motor impairments affect walking kinematics in Parkinson disease patients: A cross-sectional study
por: Liguori, Sara, et al.
Publicado: (2021)

A transient third cranial nerve palsy as presenting sign of spontaneous intracranial hypotension
por: Russo, Antonio, et al.
Publicado: (2011)

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson’s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

The effects of safinamide on dysphagia in Parkinson’s disease
por: Hirano, Makito, et al.
Publicado: (2023)

Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
por: Cilia, Roberto, et al.
Publicado: (2023)

Speech Rhythm Variation in Early-Stage Parkinson's Disease: A Study on Different Speaking Tasks
por: Maffia, Marta, et al.
Publicado: (2021)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

Olfactory loss and brain connectivity after COVID‐19
por: Esposito, Fabrizio, et al.
Publicado: (2022)

Olfactory Loss and Brain Connectivity after COVID-19: Structural Follow-Up at One Year
por: Esposito, Fabrizio, et al.
Publicado: (2023)

Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations
por: Fernandes, Mariana, et al.
Publicado: (2021)

Investigational agents in the treatment of Parkinson’s disease: focus on safinamide
por: Malek, Naveed M, et al.
Publicado: (2012)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
por: Stocchi, Fabrizio, et al.
Publicado: (2016)

Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
por: Müller, Thomas
Publicado: (2016)

The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease
por: Espinoza-Vinces, Christian, et al.
Publicado: (2023)

Cognitive dysfunctions and psychological symptoms in migraine without aura: a cross-sectional study
por: Santangelo, Gabriella, et al.
Publicado: (2016)

The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuations
por: Wei, Qianqian, et al.
Publicado: (2022)

Cluster headache pathophysiology: What we have learned from advanced neuroimaging
por: Silvestro, Marcello, et al.
Publicado: (2022)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
por: Cattaneo, Carlo, et al.
Publicado: (2018)

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
por: Sharaf, Joudi, et al.
Publicado: (2022)

Functional Connectivity Signatures of Parkinson’s Disease
por: Tessitore, Alessandro, et al.
Publicado: (2019)

Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLE
por: Cattaneo, Carlo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m6ojadbom488dqu5rg741bpjup